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Abstract
Verbal autopsies (VA) are widely used to provide cause-specific mortality estimates in de-
veloping world settings where vital registration does not function well. VAs assign cause(s)
to a death by using information describing the events leading up to the death, provided by
care givers. Typically physicians read VA interviews and assign causes using their expert
knowledge. Physician coding is often slow, and individual physicians bring bias to the coding
process that results in non-comparable cause assignments. These problems significantly limit
the utility of physician-coded VAs. A solution to both is to use an algorithmic approach that
formalizes the cause-assignment process. This ensures that assigned causes are comparable
and requires many fewer person-hours so that cause assignment can be conducted quickly
without disrupting the normal work of physicians. Peter Byass’ InterVA method (Byass
et al., 2012) is the most widely used algorithmic approach to VA coding and is aligned with
the WHO 2012 standard VA questionnaire (Leitao et al., 2013).
The statistical model underpinning InterVA can be improved; uncertainty needs to be quan-
tified, and the link between the population-level CSMFs and the individual-level cause as-
signments needs to be statistically rigorous. Addressing these theoretical concerns provides
an opportunity to create new software using modern languages that can run on multiple plat-
forms and will be widely shared. Building on the overall framework pioneered by InterVA,
our work creates a statistical model for automated VA cause assignment.
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1 Introduction
Verbal autopsy (VA) is a common approach for determining cause of death in regions
where deaths are not recorded routinely. VAs are a standardized questionnaire adminis-
tered to caregivers, family members, or others knowledgeable of the circumstances of a
recent death with the goal of using these data to infer the likely causes of death (Byass
et al., 2012). The VA survey instrument asks questions related to the deceased individ-
ual’s medical condition (did the person have diarrhea, for example) and related to other
factors surrounding the death (did the person die in an automotive accident, for exam-
ple). VA has been widely used by researchers in Health and Demographic Surveillance
Sites (HDSS), such as the INDEPTH Network (Sankoh and Byass, 2012), and has recently
received renewed attention from the World Health Organization through the release of an up-
date to the widely used standard VA questionnaire (see http://www.who.int/healthinfo/
statistics/verbalautopsystandards/). The main statistical challenge with VA data is
to ascertain patterns in responses that correspond to a pre-defined set of causes of death.
Typically the nature of such patterns is not known a priori and measurements are subject
to various types of measurement error, which are discussed in further detail below.
There are two credible methods for automating the assignment of cause of death from VA
data. InterVA (see for example: Byass et al., 2003, 2006, 2012) is a proprietary algorithm
developed and maintained by Peter Byass, and it has been used extensively by both the AL-
PHA (Maher et al., 2010) and INDEPTH networks of HDSS sites and a wide variety of other
research groups. At this time InterVA appears to be the de facto standard method. The
Institute for Health Metrics and Evaluation (IHME) have proposed a number of additional
methods (for example: Flaxman et al., 2011; James et al., 2011; Murray et al., 2011), some of
which build on earlier work by King and Lu (King et al., 2010; King and Lu, 2008). Among
their methods, the Simplified Symptom Pattern Recognition (SSPR) method (Murray et al.,
2011) is most directly comparable to InterVA and appears to have the best chance of becom-
ing widely used. The SSPR and related methods require a so-called ‘gold standard’ database,
a database consisting of a large number of deaths where the cause has been certified by medi-
cal professionals and is considered reliable, and further, where the symptoms for those deaths
are also verifiable by medical professionals. Deaths recorded in a gold standard database
are typically in-hospital deaths. Given regional variation in the prevalence and familiarity of
medical professionals with certain causes of death, region-specific gold standard databases
are also necessary. The majority of public health and epidemiology researchers and officials
do not have access to such a gold standard database, motivating development of methods to
infer cause of death using VA data without access to gold standard databases.
Aside from the challenges related to obtaining useful gold standard training data, using VA
data to infer cause assignment is also statistically challenging because there are multiple
sources of variation and error present in VA data. We identify three sources of variation
and propose a novel method called InSilicoVA to address these sources of variation. First,
though responses on the VA instrument may be the respondents recollection or best guess
about what has happened, they are not necessarily accurate. This type of error is present
in all survey data but may be especially pronounced in VA data because respondents have
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varying levels of familiarity with the circumstances surrounding a death. Also, the definition
of an event of interest may be different for each respondent. A question about diarrhea,
for example, requires the respondent to be sufficiently involved in the decedent’s medical
care to know this information and to have a definition of diarrhea that maps relatively
well to accepted clinical standards. A second source of variability arises from individual
variation in presentation of diseases. Statistical methods must be sufficiently robust to
overfitting to appreciate that two individuals with the same cause of death may have slightly
different presentations, and thus, different VA reports. Third, like InterVA, InSilicoVA
will use physician elicited conditional probabilities. These probabilities, representing the
consensus estimate of the likelihood that a person will experience a given symptom if they
died from a certain cause, are unknown. Simulation and results with data from the Agincourt
MRC/Wits Rural Public Health and Heath Transitions Research Unit (Agincourt) indicate
that results obtained with conditional probabilities assumed fixed and known (as is done in
both InterVA and the SSPR method) can underestimate uncertainty in population cause of
death distributions. We evaluate the sensitivity to these prior probabilities.
InSilicoVA incorporates uncertainty from these sources and propagates the uncertainty be-
tween individual cause assignments and population distributions. Accounting for these
sources of error produces confidence intervals for both individual cause assignments and
population distributions. These confidence intervals reflect more realistically the complex-
ity of cause assignment with VA data. A unified framework for both individual cause and
population distribution estimation also means that additional information about individual
causes, such as physician coded VAs, can easily be used in InSilicoVA, even if physician coded
records are only available for a subset of cases. Further, we can exactly quantify the contri-
bution of each VA questionnaire item in classifying a case into a specific cause, affording the
possibility for ‘item reduction’ by identifying which inputs are most useful for discriminating
between causes. This feature could lead to a more efficient, streamlined survey mechanism
and set of conditional probabilities for elicitation.
In Section 2 we describe InterVA and present open challenges which we address with InSil-
icoVA. In Section 3 we present the InSilicoVA model. Section 4 describes applications of
both methods to simulated and real data, and Section 4.3 provides the results. We conclude
with a very brief discussion in Section 5.
2 InterVA
2.1 Byass’ Description of InterVA
Below is Byass’ summary of the InterVA method presented in Byass et al. (2012).
Bayes theorem links the probability of an event happening given a particular circumstance
with the unconditional probability of the same event and the conditional probability of the
circumstance given the event. If the event of interest is a particular cause of death, and the
circumstance is part of the events leading to death, then Bayes theorem can be applied in terms
of circumstances and causes of death. Specifically, if there are a predetermined set of possible
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causes of death C1 . . . Cm and another set of indicators I1 . . . In representing various signs,
symptoms and circumstances leading to death, then Bayes general theorem for any particular
Ci and Ij can be stated as:
P (Ci|Ij) = P (Ij |Ci)× P (Ci)
P (Ij |Ci)× P (Ci) + P (Ij |!Ci)× P (!Ci) (1)
where P (!Ci) is (1−P (Ci)). Over the whole set of causes of death C1 . . . Cm a set of probabilities
for each Ci can be calculated using a normalising assumption so that the total conditional
probability over all causes totals unity:
P (Ci|Ij) = P (Ij |Ci)× P (Ci)∑m
i=1 P (Ci)
(2)
Using an initial set of unconditional probabilities for causes of death C1 . . . Cm (which can
be thought of as P (Ci|I0)) and a matrix of conditional probabilities P (Ij |Ci) for indicators
I1 . . . In and causes C1 . . . Cm, it is possible to repeatedly apply the same calculation process
for each I1 . . . In that applies to a particular death:
P (Ci|I1...n) = P (Ij |Ci)× P (Ci|I0...n−1)∑m
i=1 P (Ci|I0...n−1)
(3)
This process typically results in the probabilities of most causes reducing, while a few likely
causes are characterised by their increasing probabilities as successive indicators are processed.
In the same article Byass describes the process of defining the conditional probabilities
P (Ij|Ci).
Apart from the mathematics, the major challenge in building a probabilistic model covering
all causes of death to a reasonable level of detail lies in populating the matrix of conditional
probabilities P (Ij |Ci). There is no overall source of data available which systematically quan-
tifies probabilities of various signs, symptoms and circumstances leading to death in terms of
their associations with particular causes. Therefore, these conditional probabilities have to be
estimated from a diversity of incomplete sources (including previous InterVA models) and mod-
ulated by expert opinion. In the various versions of InterVA that have been developed, expert
panels have been convened to capture clinical expertise on the relationships between indicators
and causes. In this case, an expert panel convened in Geneva in December 2011 and contin-
ued to deliberate subsequently, particularly considering issues that built on previous InterVA
versions. Experience has shown that gradations in levels of perceived probabilities correspond
more to a logarithmic than linear scale, and in the expert consultation for InterVA-4, we used a
perceived probability scale that was subsequently converted to numbers on a logarithmic scale
as shown below.
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Table 1: InterVA Conditional
Probability Letter-Value
Correspondances
Label Value Interpretation
I 1.0 Always
A 0.8 Almost always
A 0.5 Common
A 0.2
B 0.1 Often
B 0.05
B 0.02
C 0.01 Unusual
C 0.005
C 0.002
D 0.001 vRare
D 0.0005
D 0.0001
E 0.00001 Hardly ever
N 0.0 Never
The physician-derived conditional probabilities that are supplied with the InterVA software
(Byass, 2013) are coded using the letter codes in the leftmost column of Table 1.
We rewrite, interpret and discuss the InterVA model below.
2.2 Our Notation for InterVA:
• Deaths: yj j ∈ {1, . . . , J}, ~Y = [y1, . . . , yJ ]
• Signs/symptoms: sk ∈ {0, 1}, k ∈ {1, . . . , K}, ~S = [s1, . . . , sK ]
• Causes: cn n ∈ {1, . . . , N},
∑N
n=1 cj,n = 1
• Fraction of all deaths that are cause n, the ‘cause-specific mortality fraction’ (CSMF):
fn n ∈ {1, . . . , N}, ~F = [f1, . . . , fN ],
∑N
n=1 fn = 1
2.3 Our Description of InterVA Data Requirements:
1. For each death yj, a VA interview produces a binary-valued vector of signs/symptoms:
~Sj = {sj,1, sj,2, . . . sj,K} (4)
S is the J ×K matrix whose rows are the ~Sj for each death.
2. A K ×N matrix of conditional probabilities reflecting physicians’ opinions about how
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likely a given sign/symptom is for a death resulting from a given cause:
P =

Pr(s1|c1) Pr(s1|c2) · · · Pr(s1|cN)
Pr(s2|c1) Pr(s2|c2) · · · Pr(s2|cN)
...
...
. . .
...
Pr(sK |c1) Pr(sK |c2) · · · Pr(sK |cN)
 (5)
As supplied with the InterVA software (Byass, 2013) P does not contain internally con-
sistent probabilities1. This is easy to understand by noting that these probabilities are
not derived from a well-defined event space that would constrain them to be consistent
with one another. As described by Byass above in Section 2.1 the physicians provide
a ‘letter grade’ for each conditional probability, and these correspond to a ranking
of perceived likelihood of a given sign/symptom if the death is due to a given cause.
These letter grades are then turned into numbers in the range [0, 1] (NB: 0.0 and 1.0
are included) using Table 1.
Consequently it is not possible to assume that the members of P will behave as expected
when one attempts to calculate complements and use more than one in an expression
in a way that should be consistent.
3. An initial guess of ~F , ~F ′ = [f ′n, . . . , f
′
N ]
2.4 Our Presentation of the InterVA Model and Algorithm
For a specific death yj we can imagine and examine the two-dimensional joint distribution
(cj,n, sj,k):
Pr(cj,n|sj,k) = P (sj,k|cj,n) · Pr(cj,n)
Pr(sj,k)
=
Pr(sj,k|cj,n) · Pr(cj,n)
Pr(sj,k|cj,n) · Pr(cj,n) + x (6)
where
x = Pr(sj,k|¬cj,n) · Pr(¬cj,n) (7)
Looking on the RHS of (6), we have Pr(sj,k|cj,n) from the conditional probabilities from
physicians and Pr(cj,n) ≈ f ′n. If the conditional probabilities P were well-behaved, then
x =
N∑
n′=1, n′ 6=n
Pr(sj,k|cj,n′) · Pr(cj,n′) (8)
1 The P supplied with InterVA has many logical inconsistencies, for example situations where con-
ditional probabilities should add up to equal another: Pr(fast breathing for 2 weeks or longer | HIV) +
Pr(fast breathing for less than 2 weeks | HIV) 6= Pr(fast breathing | HIV), or where they just do not make
sense: Pr(fast breathing for 2 weeks or longer | sepsis) > Pr(fast breathing | sepsis). The P supplied with
InterVA-4 (Byass, 2013) is a 254 × 69 matrix with 17,526 entries. We have investigated automated ways
of correcting the inconsistencies, but with every attempt we discover more, so we have concluded that the
entries in P need to be re-elicited from physicians using an approach that ensures that they are consistent.
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However since the P supplied with the InterVA software (Byass, 2013) are not consistent
with one another this calculation does not produce useful results.
InterVA solves this with an arbitrary reformulation of the relationship. For each death yj
and over all signs/symptoms sk associated with yj:
∀ (j, n) : Propensity(cj,n| ~Sj) = f ′n ·
K∏
k=1
[Pr(sj,k|cn)]sk (9)
For each death yj these ‘Propensities’ do not add to 1.0 so they need to be normalized to
produce well-behaved probabilities:
∀ (j, n) : Pr(cj,n) = Propensity(cj,n|
~Sj)∑N
n=1 Propensity(cj,n| ~Sj)
(10)
The population-level CSMFs ~F are calculated by adding up the results of calculating (10)
for all causes for all deaths:
∀ n : fn =
J∑
j=1
Pr(cj,n) (11)
2.5 Evaluation of InterVA Model & Algorithm
In effect what InterVA does is distribute a given death among a number of predefined causes.
The cause with the largest fraction is assumed to be the primary cause, followed with decreas-
ing significance by the remaining causes in order from largest to smallest. The conceptual
construct of a ‘partial’ death is central to InterVA and is interchanged freely with the prob-
ability of dying from a given cause. This equivalence is not real and is at the heart of the
theoretical problems with InterVA.
At a high level InterVA proposes a very useful solution to the fundamental challenge that
all automated VA coding algorithms face - how to characterize and use the relationship
that exists between signs/symptoms and causes of death. In a perfect world we would have
medically certified patient records that include the results of ‘real’ autopsies, and we could
use those to model this relationship and use the results of that model in our cause-assignment
algorithms. But in that perfect world there is no use for VA at all. So by definition we live
in the world where that type of ‘gold standard’ data do not and will not exist most of the
time for most of the developing world where VAs are conducted. Byass’ solution to this is
to accept the limitations on the expert knowledge that physicians can provide to substitute
for gold standard data, and further, to elicit and then organize that information in a very
useful format – the conditional probabilities matrix P above in (5). In sum, Byass has sorted
through a variety of possible general strategies and settled on one that is both doable and
produces useful results.
Where we contribute is to help refine the statistical and computational methods used to
conduct the cause assignments. In order to do that we have evaluated InterVA thoroughly,
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and we have identified a number of weaknesses that we feel can be addressed. The brief
list below is by necessity a blunt description of those weaknesses, which nevertheless do not
reduce the importance of InterVA as described just above.
There are several theoretical problems with the InterVA model:
1. The derivation presented in (1) through (3) is incorrect; in particular (2) does not follow
from (1), and (3) does not follow from (2). As described just above, (11) requires that
probabilities be equated with fractional deaths, which is conceptually difficult.
2. InterVA’s statistical model is not ‘probabilistic’ in the recognized sense because it
does not include elements that can vary unpredictably, and hence there is no random-
ness. Although P contains ‘probabilities’ (see discussion with (5) above), these are
not allowed to vary in the estimation procedure used to assign causes of death – P is
effectively a fixed input to the model.
3. Because the model does not contain features that are allowed to vary unpredictably, it
is not possible to quantify uncertainty to produce probabilistic error bounds.
4. If we ignore the errors in the derivation and work with (9) - (11) as if they were correct,
there are additional problems. Equation (9) is at the core of InterVA and demonstrates
two undesirable features:
(a) For a specific individual the propensity for each cause is deterministically affected
by f ′n, what Byass terms the ‘prior’ probability of cause n, effectively a user-
defined parameter of the algorithm. This means that the final individual-level
cause assignments are a deterministic transformation of the so-called ‘prior’ – i.e.
the results are not only sensitive to but depend directly on the ‘prior’.
(b) The expression in (9) captures only one valance in the relationship between
signs/symptoms and a cause of death – it acknowledges and reacts only to the
presence of a sign/symptom but not to its absence, effectively throwing away half
of the information in the dataset. To include information conveyed by the absence
of a sign/symptom, (9) needs a term that involves something like ‘1−Pr(sj,k|Cn)’.
[The components of InSilicoVA in (22) and (27) below include this term.] This is
undesirable for two reasons: (1) signs/symptoms are not selecting causes that fit
and de-selecting causes that don’t, but rather just de-selecting causes, and (2) the
final probabilities are typically the product of a large number of very small num-
bers, and hence their numeric values can become extremely small, small enough to
interact badly and unpredictable with the numerical storage/arithmetic capacity
of the software and computers used to calculate them. A simple log transforma-
tion would solve this problem.
5. Finally, (11) is a deterministic transformation of the individual-level cause assignments
to produce a population-level CSMF; simply another way of stating the individual-level
cause assignments. Because the individual-level cause assignments are not probabilis-
tic, neither are the resulting CSMFs.
In addition there are idiosyncrasies that affect the current implementation of InterVA (Byass,
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2013) and some oddities having to do with the matrix of conditional probabilities provided
with Byass’ InterVA. We will not describe those here.
InSilicoVA is designed to overcome these problems and provide a valid statistical framework
on which further refinements can be built.
3 InSilicoVA
InSilicoVA is a statistical model and computational algorithm to automate assignment of
cause of death from data obtained by VA interviews. Broadly the method aims to:
• Follow in the footsteps of InterVA building on its strengths and addressing its weak-
nesses.
• Produce consistent, comparable cause assignments and CSMFs.
• Be statistically and computationally valid and extensible.
• Provide a means to quantify uncertainty.
• Be able to function to assign causes to a single death.
The name ‘InSilicoVA’ is inspired by ‘in-vitro’ studies that mimic real biology but in more
controlled circumstances (often on ‘glass’ petri dishes). In this case we are assigning causes
to deaths using a computer that performs the required calculations using a silicon chip.
Further, we owe a great debt to the InterVA (interpret VA) method that provides useful
philosophical and practical frameworks on which to build the new method - so we have stuck
to the structure of InterVA’s name.
3.1 InSilicoVA Notation:
• Deaths: yj j ∈ {1, . . . , J}, ~Y = [y1, . . . , yJ ]
• Signs/symptoms: sk ∈ {0, 1}, k ∈ {1, . . . , K}, ~S = [s1, . . . , sK ]
• Causes of death: cn n ∈ {1, . . . , N}, ~C = [c1, . . . , cN ]
• For individual j, probability of cause n given ~Sj: `j,n = Pr(yj = cn| ~Sj), j ∈ {1, . . . , J},
n ∈ {1, . . . , N}, ~Lj = [lj,1, . . . , lj,N ],
∑N
n=1 `j,n = 1
• Count of all deaths that are cause n, the ‘cause-specific death count’ (CSDC):
mn n ∈ {1, . . . , N}, ~M = [m1, . . . ,mN ],
∑N
n=1mn = J
• Fraction of all deaths that are cause n, the ‘cause-specific mortality fraction’ (CSMF):
fn n ∈ {1, . . . , N}, ~F = [f1, . . . , fN ],
∑N
n=1 fn = 1
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3.2 InSilicoVA Data:
1. For each death yj, the VA interview produces a binary-valued vector of signs/symptoms:
~Sj = {sj,1, sj,2, . . . sj,K} (12)
S is the J × K matrix whose rows are the ~Sj for each death. The columns of S are
assumed to be independent given ~C, i.e. there is no systematic relationship between the
signs/symptoms for a given cause. This is very obviously not a justifiable assumption.
Signs and symptoms come in characteristic sets depending on the cause of death, so
there is some correlation between them, conditional on a given cause. Nonetheless we
assume independence in order to facilitate initial construction and testing of our model,
and most pragmatically, so that we can utilize the matrix of conditional probabilities
supplied by Byass with the InterVA software (Byass, 2013) – it is impossible to either
regenerate or significantly improve upon these without significant resources with which
to organize meetings of physicians with the relevant experience who can provide this
information. This ~Sj is the same as (4) used by InterVA.
2. A K ×N matrix of conditional probabilities reflecting physicians’ opinions about how
likely a given sign/symptom is for a death resulting from a given cause:
P =

Pr(s1|c1) Pr(s1|c2) · · · Pr(s1|cN)
Pr(s2|c1) Pr(s2|c2) · · · Pr(s2|cN)
...
...
. . .
...
Pr(sK |c1) Pr(sK |c2) · · · Pr(sK |cN)
 (13)
InSilicoVA assumes that the components of P are consistent with one another. In the
simulation study described in Section 4.1, we construct consistent values for P, but
when we test the model on real data in Section 4.2, we have no option other than using
the inconsistent P supplied with the InterVA software (Byass, 2013).
3. An initial guess of ~F , ~F ′ = [f ′n, . . . , f
′
N ]
3.3 InSilicoVA Algorithm
We are interested in the joint distribution (~F , ~Y ) given the set of observed signs/symptoms
S. The posterior distribution is:
Pr(~F , ~Y |S) = Pr(S|
~Y , ~F ) Pr(~Y |~F ) Pr(~F )
Pr(S)
∝ Pr(S|~Y , ~F ) Pr(~Y |~F ) Pr(~F ) (14)
=
J∏
j=1
Pr(S|yj, ~F ) Pr(yj|~F ) Pr(~F ) (15)
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Because individual cause assignments are independent, individual sign/symptom vectors ~Sj
are independent from ~F (the CSMFs), and we have:
Pr(~F , ~Y |S) ∝
J∏
j=1
Pr(S|yj) Pr(yj|~F ) Pr(~F ) (16)
We will use a Gibbs sampler to sample from this posterior as follows:
G.1 start with an initial guess of ~F , ~F ′
G.2 sample ~Y |~F ,S
G.3 sample ~F |~Y ,S
G.4 repeat steps G.2 and G.3 until ~F and ~Y converge
This algorithm is generic and allows a rich range of models. For the moment the InsilicoVA
model is:
sj,k|cn ∼ Bernoulli(Pr(sj,k|cn)) (17)
yj = cn|~F ∼ MultinomialN(1, ~F ) (18)
~F ∼ Dirichlet(~α), ~α is N -dimensional and constant (19)
Then the posterior in (16) is:
Pr(~F , ~Y |S) ∝
J∏
j=1
K∏
k=1
Pr(sj,k|yj = cn) Pr(yj = cn|~F ) Pr(~F ) (20)
This formulation is computationally efficient because of Multinomial/Dirichlet conjugacy,
and because using Bayes rule we have, for step G.2:
yj = cn|~F , ~Sj ∼ MultinomialN(1, ~Lj) (21)
where the `j,n that compose ~Lj are:
`j,n = Pr(yj = cn| ~Sj)
=
Pr(yj = cn) · Pr( ~Sj|yj = cn)
Pr( ~Sj)
substituting fn = Pr(yj = cn) and using the data ~Sj and P to calculate
the probability of a specific ~Sj given the cause assignment yj = cn
=
fn ·
∏K
k=1
(
Pr(sj,k|yj = cn)sj,k · [1− Pr(sj,k|yj = cn)](1−sj,k)
)
∑N
n′=1 fn′ ·
∏K
k=1
(
Pr(sj,k|yj = cn′)sj,k · [1− Pr(sj,k|yj = cn′)](1−sj,k)
) (22)
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We can also derive from (20) the distribution of ~F conditional on ~Y , for step G.3:
~F |~Y ,S ∼ Dirichlet( ~M + ~α) (23)
where
mn =
J∑
j=1
[yj = cn], using Iverson’s bracket notation:[z] =
{
1 if z true
0 if z false
(24)
In summary, the Gibbs sampler proceeds given suitable initialization ~F ′ by:
G.2 sampling a cause for each death to generate a new ~Y |~F ,S:
yj = cn|~F , ~Sj ∼ MultinomialN(1, ~Lj) (25)
where
`j,n =
fn ·
∏K
k=1
(
Pr(sj,k|yj = cn)sj,k · [1− Pr(sj,k|yj = cn)](1−sj,k)
)
∑N
n′=1 fn′ ·
∏K
k=1
(
Pr(sj,k|yj = cn′)sj,k · [1− Pr(sj,k|yj = cn′)](1−sj,k)
) (26)
G.3 sampling a new ~F |~Y ,S:
~F |~Y ,S ∼ Dirichlet( ~M + ~α) (27)
The resulting sample of (~F , ~Y ) and the ~Lj that go with it form the output of the method.
These are distributions of CSMFs at the population level and probabilities of dying from
each cause at the individual level. These distributions can be summarized as required to
produce point values and measures of uncertainty in ~F and ~Lj.
Deaths often result from more than one cause. InSilicoVA accommodates this possibility by
producing a separate distribution of the probabilities of being assigned to each cause; that
is N distributions, one for each cause. In contrast, InterVA reports one value for each cause,
and those values sum to unity across causes for a single death.
Finally, with a suitable ~F , InSilicoVA can be used to assign causes (and their associated `j,n)
to a single death by repeatedly drawing causes using (25). This requires no more information
than InterVA to accomplish the same objective, and it produces uncertainty bounds around
the probabilities of being assigned to each cause.
4 Testing & Comparing InSilicoVA and InterVA
To evaluate both InSilicoVA and InterVA we fit them to simulated and real data. We have
created R code that implements both methods. The R code for InterVA matches the results
produced by Peter Byass’ implementation (Byass, 2013).
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4.1 Simulation Study
Our simulated data are generated using this procedure:
1. Draw a set of Pr(sk|cn) so that they have the same distribution and range as those
provided with Byass’ InterVA software (Byass, 2013).
2. Draw a set of simulated deaths from a made up distribution of deaths by cause.
3. For each simulated death, assign a set of signs/symptoms by applying the conditional
probabilities simulated in step 1.
These simulated data have the same overall features as the data required for either InterVA
or InSilicoVA, and we know both the real population distribution of deaths by cause and the
true individual cause assignments.
Our simulation study poses three questions:
1. Fair comparison of InSilicoVA and InterVA. To make this comparison we gen-
erate 100 simulated datasets and apply both methods to each dataset. We summarize
the results with individual-level and population-level error measures. We refer to this
as ‘fair’ because we apply both methods in their simplest form to data that fulfill all
the requirements of both methods. Since the data are effectively ‘perfect’ we expect
both methods to perform well.
2. Influence of numeric values of Pr(sk|cn). Given the structure of InterVA, we are
concerned that the results of InterVA may be sensitive to the exact numerical values
taken by the conditional probabilities supplied by physicians. To test this we rescale
the simulated Pr(sk|cn) so that their range is restricted to [0.25 − 0.75]. We again
simulate 100 datasets and apply both methods to each dataset and summarize the
resulting errors for each method.
3. Reporting errors. As we mentioned in the introduction, we are concerned about
reporting errors for any algorithmic approach to VA cause assignment. To investigate
this we randomly recode our simulated signs/symptoms so that a small fraction are
‘wrong’ - i.e. coded 0 when the sign/symptom exists (15%) or 1 when there is no
sign/symptom (10%). We do this for 100 simulated datasets and summarize errors
resulting from application of both methods.
4.2 Application to Real Data - Agincourt HDSS
To investigate the behavior of InSilicoVA and InterVA on real data, we apply both methods to
the VA data generated by the Agincourt health and demographic surveillance system (HDSS)
in South Africa (Kahn et al., 2012) from roughly 1993 to the present. The Agincourt site
continuously monitors the population of 21 villages located in the Bushbuckridge District
of Mpumalanga Province in northeast South Africa. This is a rural population living in
what was during Apartheid a black ‘homeland’. The Agincourt HDSS was established in the
early 1990s with the purpose of guiding the reorganization of South Africa’s health system.
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Since then the goals of the HDSS have evolved and now it contributes to evaluation of
national policy at population, household and individual levels. The population covered by
the Agincourt site is approximately eighty-thousand.
For this test we us the physician-generated conditional probabilities P and initial guess of
the CSMFs ~F ′ provided by Byass with the InterVA software (Byass, 2013).
4.3 Results
The results of our simulation study are summarized graphically as a set of Figures 1 – 3.
The Agincourt results are presented in Figure 4.
5 Discussion
5.1 Summary of Findings
InSilicoVA begins to solve most of the critical problems with InterVA. The results of ap-
plying both methods to simulated data indicate that InSilicoVA performs well under all
circumstances except ‘reporting errors’, but even in this situation InSilicoVA performs far
better than InterVA. InSilicoVA and InterVA both perform relatively well when the simu-
lated data are perfect. InSilicoVA’s performance is not affected by changing the magnitudes
and ranges of the conditional probability inputs, whereas InterVA’s performance suffers dra-
matically. With reporting errors both methods’ performance is negatively impacted, but
InterVA becomes effectively useless.
Applied to one specific real dataset, both methods produce qualitatively similar results, but
InSilicoVA is far more conservative and produces confidence bounds, whereas InterVA does
not. For Agincourt, Figure 4.A shows the causes with the largest difference between the In-
SilicoVA and InterVA estimates of the CSMF. InSilicoVA classifies a larger portion of deaths
as due to causes labeled as ‘other.’ This indicates that these causes are related to either
the communicable or non-communicable diseases, but there is not enough information to
make a more specific classification. This feature of InSilicoVA identifies cases that are diffi-
cult to classify using available data and may, for example, be good candidates for physician
review.
We view this behavior as a strength of InSilicoVA because it is consistent with the fun-
damental weakness of the VA approach, namely that both the information obtained from
a VA interview and the expert knowledge and/or gold standard used to characterize the
relationship between signs/symptoms and causes are inherently weak and incomplete, and
consequently it is very difficult or impossible to make highly specific cause assignments using
VA. Given this, we do not want a method that is artificially precise, i.e. forces fine-tuned
classification when there is insufficient information. Hence we view InSilicoVA’s behavior
as reasonable, ‘honest’ (in that it does not over interpret the data) and useful. ‘Useful’ in
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the sense that it identifies where our information is particularly weak and therefore where
we need to apply more effort either to data or to interpretation, like addition physician
reviews.
5.2 Future Work
We plan a variety of additional work on InSilicoVA:
1. Explore the possibility of replacing the Dirichlet distribution in (19), (23) and (27)
with a mixture of Normals on the baseline logit transformed set of fn’s. This provides
additional flexible parameters to allow each CSMF to have its own mean and variance.
2. Embed InSilicoVA in a spatio-temporal model that allows ~F to vary smoothly through
space and time. This would provide a parsimonious way of exploring spatio-temporal
variation in the CSMFs while using the data as efficiently as possible.
3. Create the ability to add physician cause assignments to (22) and (26) so that infor-
mation in that form can be utilized when available. The physician codes will require
pre-processing to remove physician-specific bias in cause assignment, perhaps using a
‘rater reliability method’ (for example: Salter-Townshend and Murphy, 2012).
4. Most importantly, address the obviously invalid assumption that the signs/symptoms
are independent given a specific cause. This will require modeling of the signs/symptoms
and the physician-provided conditional probabilities so that important dependencies
can be accommodated. Further, this will require additional consultation with physi-
cians and acquisition of new expert knowledge to characterize these dependencies. All
of this will require a generous grant and the collaboration of a large number of experts.
This will very likely greatly improve the performance and robustness of the method.
5. Critically, re-elicit the conditional probabilities P from physicians so that they are
logically well-behaved, i.e. fully consistent with one another and their complements.
6. Focus and sharpen VA questionnaire. Quantify the influence of each sign/symptom to:
(1) potentially eliminate low-value signs/symptoms and thereby make the VA interview
more efficient, and/or (2) suggest sign/symptom ‘types’ that appear particularly useful,
and potentially suggest augmenting VA interviews based on that information.
7. Explore new possibilities for refining the conditional probabilities P and potentially
for entirely new models.
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Figure 1: Simulation setup 1: ‘Fair Comparison’. A: InSilicoVA correctly assigns
cause of death correctly effectively 100% of the time. InterVA is less accurate
in assigning individual causes of death. B: InSilicoVA’s errors in identifying
CSMFs are consistently very small. InterVA’s errors are also generally small,
but the distribution has a long tail in the direction of large errors – sometimes
InterVA’s errors are large.
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Figure 2: Simulation setup 2: ‘Conditional Probabilities in the range [0.25−0.75]’.
A: InSilicoVA correctly assigns cause of death correctly effectively 100% of the
time. InterVA correctly assigns cause of death correctly 80% of the time with
wide variation all the way down to as low as 60% and never above about 90%. B:
InSilicoVA’s errors in identifying CSMFs are consistently very small. InterVA’s
errors in identifying the CSMFs are larger and more variable.
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Figure 3: Simulation setup 3: ‘Reporting Errors’. Both methods suffer, but InterVA
suffers a lot more. A: InSilicoVA correctly assigns cause of death correctly about
70% of the time. InterVA correctly assigns cause of death correctly about 40%
of the time. B: InSilicoVA’s errors in identifying CSMFs are still consistently
small. InterVA’s errors in identifying the CSMFs are larger.
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Figure 4: Agincourt Application. A: Differences in CSMFs (InSilicoVA – InterVA)
displaying the 10 specific causes that differ most. InSilicoVA is less willing to
make highly specific classifications and thus produces larger CSMFs associated
with less-specific causes and smaller CSMFs associated with more specific causes.
B: Same as (A) but for the 10 largest differences in CSMFs that are still less than
4%, which as a group includes HIV even though it is not in the top 10 that are
plotted here. C: The CSMFs produced by both models on their natural scale,
the same 10 causes as in A for which the differences are greatest.
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